Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Anaprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anaprozole Sodium Enteric-coated Tablet is currently the first and only proton pump inhibitor, which is investigated for the treatment of duodenal ulcer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Anaprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KM257
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Xuanzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Xuanzhu Biopharm Acquires Combio Pharmaceutical
Details : Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.
Product Name : KM257
Product Type : Antibody
Upfront Cash : Undisclosed
January 27, 2021
Lead Product(s) : KM257
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Xuanzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Anaprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases
Details : The results of the completed phase II clinical trial showed that Anaprazole is effective in treating duodenal ulcer, conducive to ulcer healing and relieves ulcer-related symptoms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2020
Lead Product(s) : Anaprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sihuan Announces Clinical Research of Favipiravir, Co-Developed
Details : The Trials are random, parallel dose exploration studies with three dosage groups (high, middle and low dosage) to explore the best treatment regimen of Favipiravir for COVID-19 patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable